The company started a high-resolution magnetic survey of its entire, recently increased nickel-copper property package in Ontario, noted a Research Capital Corp. report.
It is now estimated that nameplate capacity production should be achieved at this polymetallic project in Mexico sometime in mid- to late 2023, noted a Canaccord Genuity report.
Plans call for an initial clinical trial to start in H1/23 in both the U.S. and the United Kingdom, where the biopharma recently received approval to proceed, noted an H.C. Wainwright & Co. report.
The results, just in for the final holes of the company's 2022 drill campaign, include the highlight intercept, 3.66% total rare earth oxides over 138 meters, noted a Noble Capital Markets report.
The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial, noted an H.C. Wainwright & Co. report.
This tranche, other cash and cash equivalents, and current cash flow are sufficient to get the developer of immunotherapeutics through 2023, noted an H.C. Wainwright & Co. report.
New drill results from this project in British Columbia returned a total rare earth oxide grade of 3.77% and an intercept length of 222m, noted a Noble Capital Markets report.
This property, near the company's flagship and one of the world's largest gold-copper projects, returned drill results that warrant following up, noted a Cantor Fitzgerald report.
The defense manufacturer "got off to a flying start in the new year" with this new contract and an increase in its target price, noted a Bell Potter report.
Drilling at this Colombia property and metallurgical testing continue ahead of the maiden resource estimate due out in Q1/23, noted a Research Capital Corp. report.
Connection of the firm's newly constructed mill there to the area's electrical grid was recently completed, testing was done and commissioning was commenced, noted a ROTH Capital Partners report.
Because of the green light from the U.S. Food and Drug Administration, H.C. Wainwright & Co. raised its target price on the developer of this drug, according to a recent report.
The company that owns this project offers investors significant potential return and is Speculative Buy rated, noted a Laurentian Bank Securities report.
The transformational acquisition of interests in various oilfield-holding licenses is expected to generate "substantial free cash flow," noted a Research Capital Corp. report.
These upcoming events relate to this firm's efforts to get one or more of its technologies integrated into an existing product and sold commercially, noted a Water Tower Research report.